Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

John Harris has just been awarded an honorary MA in recognition of 50 years of service to the Department of Pharmacology and reflects on highlights over the past five decades

John Harris (left) receives his honorary MA at the Sheldonian Theatre. © Ian Wallman

He may have just received an honorary MA in recognition of 50 years’ service to the Department of Pharmacology, but John Harris still recalls his first day nerves aged 19.

“I think it was actually my mum who saw the job advertised,” said Oxford-born John, who started out as a Junior Technician in the Department of Pharmacology Workshop in 1969.

“I remember I came in early on my first day and I was a little bit nervous.

“I was mainly building things for the researchers in the labs and making sure everything was working in the classrooms for the medical students.”

John has remained in the workshop ever since and past his 50-year milestone in October 2019, when the department held a reception for him. Then, on 29 February 2020, he received his honorary MA at the Sheldonian Theatre.

“Everyone made me feel so special on the day,” said John, who particularly enjoyed part of the ceremony outside afterwards where, as a member of the procession, he had to doff his cap to applauding students who had received their degrees.

Read the full story on the University of Oxford website

Similar stories

Prestigious award for Oxford professor's diabetes work

A University of Oxford professor has been awarded the 2021 EASD-Novo Nordisk Foundation Prize for Excellence for his decades of effort to understand, prevent and combat type 1 diabetes.

Wellcome accolades for Dr Douglas

Dr Alexander (Sandy) Douglas, an investigator at the Jenner Institute, Nuffield Department of Medicine, has recently received two prestigious Wellcome accolades.

FOCUS4: a flagship trial in colorectal cancer

Professor Tim Maughan (Department of Oncology) outlines the flagship work of the FOCUS4 trials, whose results were presented last weekend at the European Society of Medical Oncology (ESMO) annual meeting

Oxford and Oracle partner to speed identification of COVID-19 variants

The fast spread of the highly infectious Delta variant underscores the need for faster identification of COVID-19 mutations. Uniting governments and medical communities in this challenge, the University of Oxford and Oracle’s Global Pathogen Analysis System (GPAS) is now being used by organizations on nearly every continent. Institutions using the platform include: the University of Montreal Hospital Centre Research Centre, the Institute of Public Health Research of Chile, the Oxford University Clinical Research Unit in Vietnam, the Institute of Clinical Pathology and Medical Research – New South Wales Pathology, and Oxford Nanopore Technologies. GPAS is also now part of the Public Health England New Variant Assessment Platform.

Vaccinated groups at highest risk of Covid-19 hospitalisation and death identified using new QCovid tool

Researchers from the University of Oxford have today reported on findings on the vaccinated people who are at greatest risk from severe Covid-19 leading to hospitalisation or death from 14 days post the second dose vaccination, when substantial immunity should be expected.